You all know that AMESA was formed by ECF owners and moderators.
Purpose
The purpose of these Standards is to create a responsible and sustainable practices and process for the safe manufacturing of
“e-liquids” used in electronic cigarettes. Our members believe we have a responsibility to self-regulate the e-liquid manufacturing
process based on professional criteria. AEMSA aims to accomplish this by creating, implementing and upholding standards for
the manufacture of e-liquids. One of AEMSA’s primary goals is to provide consumers with higher degrees of confidence our
members’ products are manufactured with professionalism, accuracy and safety
AEMSA standards are established based on the following Core Beliefs:
• We have a responsibility to verify the accuracy of any nicotine content in the products we distribute.
• We have a responsibility to ensure the quality and safety of all ingredients in our e-liquids.
• We have a responsibility to prepare our products in a clean, sanitary and safe environment.
• We have a responsibility to ensure our products are packaged and delivered in a safe manner.
• We have a responsibility to provide a level of transparency into the monitoring and verification process.
No Arguments here.
BTW - I wonder How Much of All this does Mr. Zeller have Complete Control over? I mean, he Doesn't even run the FDA.
Right?
I Also think he Understand the He is a Cog in a Very Large Piece of Machinery.
Right. He's head of the Center of Tobacco Products (CTP) but responsible for much of the deeming.
New head of FDA: Robert Califf
Who is Dr. Robert Califf, the New Head of the FDA?
Just following orders?![]()
...
Not so Much that. Just that Mr. Zeller doesn't have All the Say in what is Done.
Ok, ok. Maybe it's time to vote John Q. Public or Joe Average as a write in [emoji23]. Yea that's it!! Vote for Joe Average and Jane can be first lady[emoji23][emoji23]I've tried that. Ended up with a current candidate![]()
To which part?I respectfully and strongly disagree.
with respect to the risks and benefits to the population as a whole, including users and nonusers of the tobacco product, and taking into account ─ (A) the increased or decreased likelihood that existing users of tobacco products will stop using such products; and (B) the increased or decreased likelihood that those who do not use tobacco products will start using such products.
You all know that AMESA was formed by ECF owners and moderators. Yeah it makes money for them but is nothing more than paying for Kosher certified through the Jewish mafia. RTS has forgot more than AMESA knows. Their fee of $5,000 per month to RTS, based on volume, is ridiculous for a group that adds no value. We have been working all year to get FDA certification which really matters.
Sorry Zoid. I was using the kindle at the bar. I don't know what happened but, those are not the quotesPlease site were whatever you are Referring to. And Please Clarify what you are trying to say when you Used the term "Out Sourced".
---
And Yes. Seriously.
Sorry Zoid. I was using the kindle at the bar. I don't know what happened but, those are not the quotes
I was commenting too. there not even close. As I remember the first quote was to Kent and the second
was some one else. Any I apologize for the screw up. I'm new to touch screens.
Regards
Mike
...
As I see it, the rules for tobacco products are:
1. can't be shown to attract non-users to start(which they all inevitably do)
2. Can't be shown to prevent someone from quitting tobacco altogether, if that's possibly what they would have done otherwise.
Number 2 would be the sticking point with vapor products, I think.
Well, here are the guidelines for the "public health" study portion of the PMTA, it's more about HOW to conduct them though. For the acceptable thresholds, I suppose you could try to view previous PMTA applications that have been approved and compare them to those that haven't, if those are available. I think they might be, but I also seem to recall seeing one that was severely redacted.Does the PMTA Guidance say that something "Can't be Shown"?
Or is it seeking the Likelihood in which Lower would be Better?
A. General Principles for Scientific Studies Under section 910(c)(4) of the FD&C Act, your new tobacco product will be evaluated to determine whether the product is appropriate for the protection of the public health considering the risks and benefits, including the health risks of the product and the likelihood of changes in initiation and cessation rates. These considerations will allow for an evaluation of the impact of the new tobacco product on morbidity and mortality for the population as a whole. In demonstrating the public health impacts of the product, data from your well-controlled scientific investigations should address, among other things, the following questions:
(1) How do the health risks associated with your product compare to the health risks of other products on the market? How do the health risks of switching from another tobacco product to your product compare to the health risks associated with quitting the use of tobacco products? How do the health risks associated with your product compare to never using tobacco products? Accordingly, your scientific studies regarding health risks of your new tobacco product should allow for a comparison of the health risks of your tobacco product to the risks associated with quitting, using other tobacco products, and never using tobacco products.
(2) How will your new tobacco product affect the likelihood that current tobacco users will cease using tobacco products? In making this evaluation, you should address the attractiveness of your product and product labeling to current tobacco users (especially to those users interested in quitting smoking), the addictiveness and abuse liability of your product, and cessation rates associated with users who switch to your new tobacco product. Additionally, you should provide evidence regarding the likelihood that your new product will be used concurrently with other tobacco products currently on the market. Your evaluation of the impact of the introduction of your new tobacco product on cessation rates should provide data on the attractiveness, addictiveness, and cessation rates of your new tobacco product as compared to other tobacco products currently on the market.
(3) How will your new tobacco product affect the likelihood that never-users and former-users of tobacco products will use your new tobacco product? In making this evaluation, you should address the attractiveness of your product and product labeling to never-users and former-users of tobacco products (especially to those segments of the population that may be particularly likely to initiate or reinitiate tobacco use), as well as the addictiveness and abuse liability of your product. To provide a full evaluation of the impact of your product on the market and on the population as a whole, your scientific evaluations should provide data on how the attractiveness and addictiveness of your product compares to that of products currently on the market. You should specify what product features may enhance the attractiveness/appeal of your product to children and adolescents and what product features may minimize the attractiveness/appeal of your product to children and adolescents.
All of your scientific evaluations should use control groups of comparator products and use various tobacco use levels sufficient to address the questions and considerations above. For example, in evaluating the health risks of your product, clinical studies should provide data on biomarkers for users of other tobacco products as well as biomarkers for quitters and never-users. Similarly, product chemistry evaluations should compare your new product’s chemistry to other tobacco products currently on the market. In addition, your studies should follow a pre-specified statistical analysis plan for data analysis to ensure the validity of your conclusions.
FDA encourages persons who would like to study their new tobacco product to meet with the Office of Science at the Center for Tobacco Products to discuss their investigational plan prior to distributing the product for investigational purposes (see section VII, below).
Well, here are the guidelines for the "public health" study portion of the PMTA, it's more about HOW to conduct them though. For the acceptable thresholds, I suppose you could try to view previous PMTA applications that have been approved and compare them to those that haven't, if those are available. I think they might be, but I also seem to recall seeing one that was severely redacted.
I am wondering if the President is required to act within the 90-120 days, once the regulations have been submitted to the OMB. Or, is it possible for the proposed regulations to sit in the White House indefinitely, or for at least longer than 120 days?
True, but there is the existing framework of Modified Risk Tobacco Product, and that one works so well...I think that e-Cigarettes present some Unique Challenges to the Existing Framework of the PMTA.
Because the Existing Framework, on average, has dealt with "Tobacco Products" that curtailed a much Higher Risk of Use.